Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
CA Stock MarketDetailed Quotes
Marvel Biosciences Corp (MRVL)
- 0.140
- -0.020-12.50%
15min DelayPost Market May 7 15:58 ET
8.82MMarket Cap-3.50P/E (TTM)
0.175High0.140Low195.47KVolume0.175Open0.160Prev Close30.39KTurnover0.40052wk High0.38%Turnover Ratio63.03MShares0.07552wk Low-0.04EPS TTM7.21MFloat Cap0.400Historical HighLossP/E (Static)51.52MShs Float0.010Historical Low-0.05EPS LYR21.88%Range %--Dividend TTM-2.30P/B1Lot Size--Div Yield TTM
Marvel Biosciences Corp (MRVL) Cash Flow
Quarterly+Annual
YOY
| (Q2)Jan 31, 2026 | (Q1)Oct 31, 2025 | (FY)Jul 31, 2025 | (Q4)Jul 31, 2025 | (Q3)Apr 30, 2025 | (Q2)Jan 31, 2025 | (Q1)Oct 31, 2024 | (FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -1,546.37%-434.36K | 32.01%-178.46K | 2.47%-1.15M | 3.06%-330.15K | -47.60%-531.31K | 88.98%-26.38K | -9.53%-262.48K | 11.46%-1.18M | 23.57%-340.57K | -21.56%-359.98K |
| Net income from continuing operations | 39.13%-295.58K | -23.01%-342.26K | -34.02%-2.21M | -101.17%-1.19M | 16.24%-257.41K | -108.58%-485.61K | 46.32%-278.25K | 27.99%-1.65M | 43.43%-591.65K | 57.10%-307.31K |
| Asset impairment expenditure | ---- | ---- | --72.34K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Remuneration paid in stock | -67.62%6.08K | -71.67%6.09K | -0.78%75.13K | -68.43%17.2K | 292.14%17.66K | 166.37%18.79K | 121.62%21.48K | -5.49%75.72K | 294.05%54.47K | -66.33%4.5K |
| Other non cashItems | --7.5K | --7.5K | 196.43%622.5K | ---- | ---- | ---- | ---- | --210K | ---- | ---- |
| Change In working capital | -134.60%-152.37K | 2,727.16%150.22K | 57.51%291.18K | 1,206.15%148.03K | -410.00%-291.56K | 3,349.71%440.43K | -102.13%-5.72K | -78.97%184.86K | -102.25%-13.38K | -114.34%-57.17K |
| -Change in receivables | 169.40%5.75K | 1,698.01%142.46K | -3,026.44%-123.96K | -598.49%-149.96K | 736.16%43.2K | 0.11%-8.29K | 17.14%-8.92K | 116.63%4.24K | 339.62%30.08K | 25.05%-6.79K |
| -Change in prepaid assets | 71.64%-1.67K | -35.42%5.88K | 97.96%-694 | 81.00%-8.75K | -54.64%4.85K | 20.56%-5.9K | 3.85%9.1K | -114.78%-34.01K | -140.08%-46.05K | -91.88%10.7K |
| -Change in payables and accrued expense | -134.41%-156.45K | 131.87%1.88K | 93.74%415.84K | 11,774.91%306.73K | -456.02%-339.61K | 20,840.63%454.62K | -102.18%-5.9K | -68.18%214.64K | -99.48%2.58K | -122.14%-61.08K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -1,546.37%-434.36K | 32.01%-178.46K | 2.47%-1.15M | 3.06%-330.15K | -47.60%-531.31K | 88.98%-26.38K | -9.53%-262.48K | 11.46%-1.18M | 23.57%-340.57K | -21.56%-359.98K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 75K | 683.14K | -3.64%933.41K | -85.07%69.98K | 863.43K | 0 | 0 | -25.24%968.64K | 468.64K | 0 |
| Net issuance payments of debt | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -50.00%500K | --0 | --0 |
| Net common stock issuance | ---- | ---- | 103.75%1.02M | -81.25%93.75K | ---- | ---- | ---- | 85.19%500K | 1,766.67%500K | ---- |
| Proceeds from stock option exercised by employees | --75K | --683.14K | --2.63K | --0 | --2.63K | --0 | --0 | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | -180.53%-87.97K | ---23.77K | ---- | ---- | ---- | -222.25%-31.36K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --75K | --683.14K | -3.64%933.41K | -85.07%69.98K | --863.43K | --0 | --0 | -25.24%968.64K | --468.64K | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | 660.66%633.54K | -62.73%128.86K | -37.88%345.77K | 78.70%389.02K | -89.69%59.53K | -73.72%83.29K | -37.88%345.77K | -6.17%556.62K | -78.28%217.69K | 93.64%577.67K |
| Current changes in cash | -1,412.59%-359.36K | 292.27%504.68K | -2.87%-216.91K | -303.13%-260.16K | 191.53%329.49K | -109.11%-23.76K | -9.53%-262.48K | -476.34%-210.85K | 128.75%128.08K | -151.14%-359.98K |
| End cash Position | 360.56%274.17K | 660.66%633.54K | -62.73%128.86K | -62.73%128.86K | 78.70%389.02K | -89.69%59.53K | -73.72%83.29K | -37.88%345.77K | -37.88%345.77K | -78.28%217.69K |
| Free cash from | -1,546.37%-434.36K | 32.01%-178.46K | 2.47%-1.15M | 3.06%-330.15K | -47.60%-531.31K | 88.98%-26.38K | -9.53%-262.48K | 11.46%-1.18M | 23.57%-340.57K | -21.56%-359.98K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The US-Iran negotiations have entered a critical window period amid external expectations and the strategic interactions of all parties, wit
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm